Prognostic impact of polypharmacy and discharge medications in octogenarians and nonagenarian patients with acute heart failure

• Published in: Heart and vessels Vol. 39; no. 6; pp. 514 - 523
• Main Authors: Uemura, Yusuke, Shibata, Rei, Sawada, Kazuhisa, Ishikawa, Shinji, Takemoto, Kenji, Murohara, Toyoaki, Watarai, Masato
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.06.2024; Springer Nature B.V
• Subjects: Biomedical Engineering and Bioengineering; Cardiac Surgery; Cardiology; Congestive heart failure; Diuretics; Heart failure; Medicine; Medicine & Public Health; Mineralocorticoid receptors; Mortality; Nonagenarian; Older people; Original Article; Patients; Polypharmacy; Prognosis; Vascular Surgery; Heart failure; Polypharmacy; Prognosis; Elderly
• ISSN: 0910-8327; 1615-2573
• DOI: 10.1007/s00380-024-02366-w

With the increasing frequency of heart failure (HF) in elderly patients, polypharmacy has become a major concern owing to its adverse outcomes. However, reports on the clinical impact of polypharmacy and discharge medications in hospitalized super-aged patients with acute HF are rare. Data from 682 patients aged 80 years or older, hospitalized for treating acute HF, were analyzed. We recorded the number of medications at discharge and classified them into three groups: HF, non-HF cardiovascular, and non-cardiovascular medications. We investigated the correlation of polypharmacy, defined as daily administration of 10 or more medications at discharge, and the use of discharge medications with post-discharge prognosis. Polypharmacy was recorded in 24.3% of enrolled patients. Polypharmacy was not an independent predictor of all-cause mortality, the incidence of cardiac-related death, or HF-associated rehospitalization; however, the number of non-cardiovascular medications, multiple usage of potentially inappropriate medications, use of mineralocorticoid receptor antagonists, and doses of loop diuretics were associated with poor prognosis. Polypharmacy was significantly associated with higher mortality in patients with Barthel index ≥ 60 at discharge; hence, physical function at discharge was useful for the stratification of prognostic impacts of polypharmacy. The current study demonstrated that polypharmacy was not essentially associated with poor prognosis in super-aged patients with acute HF. Appropriate medications that consider the patient’s physical function, rather than polypharmacy itself, are important for the management of HF.